Unlocking Bevacizumab's Potential : rCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients
Álvarez-Torres, María del Mar (Universitat Politècnica de València)
Balañá, Carmen (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer)
Fuster-Garcia, Elies (Universitat Politècnica de València)
Puig, Josep (Hospital Clínic i Provincial de Barcelona)
García Gómez, Juan Miguel (Universitat Politècnica de València)

Data:	2024
Resum:	Background: Aberrant vascular architecture and angiogenesis are hallmarks of glioblastoma IDH-wildtype, suggesting that these tumors are suitable for antiangiogenic therapy. Bevacizumab was FDA-approved in 2009 following promising results in two clinical trials. However, its use for recurrent glioblastomas remains a subject of debate, as it does not universally improve patient survival. Purposes: In this study, we aimed to analyze the influence of tumor vascularity on the benefit provided by BVZ and propose preoperative rCBVmax at the high angiogenic tumor habitat as a predictive biomarker to select patients who can benefit the most. Methods: Clinical and MRI data from 106 patients with glioblastoma IDH-wildtype have been analyzed. Thirty-nine of them received BVZ, and the remaining sixty-seven did not receive a second-line treatment. The ONCOhabitats method was used to automatically calculate rCBV. Results: We found a median survival from progression of 305 days longer for patients with moderate vascular tumors who received BVZ than those who did not receive any second-line treatment. This contrasts with patients with high-vascular tumors who only presented a median survival of 173 days longer when receiving BVZ. Furthermore, better responses to BVZ were found for the moderate-vascular group with a higher proportion of patients alive at 6, 12, 18, and 24 months after progression. Conclusions: We propose rCBVmax as a potential biomarker to select patients who can benefit more from BVZ after tumor progression. In addition, we propose a threshold of 7. 5 to stratify patients into moderate- and high-vascular groups to select the optimal second-line treatment.
Ajuts:	Agencia Estatal de Investigación PID2019-104978RB-I00 Agencia Estatal de Investigación PID2021-127110OA-I00 Fundació la Marató de TV3 665/C/2013
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Glioblastoma ; Predictive biomarker ; Angiogenesis ; Bevacizumab ; Rcbv
Publicat a:	Cancers, Vol. 16 Núm. 1 (january 2024) , p. 161, ISSN 2072-6694

DOI: 10.3390/cancers16010161
PMID: 38201588

15 p, 5.6 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats